Form 8-K - Current report:
SEC Accession No. 0001213900-22-008631
Filing Date
2022-02-22
Accepted
2022-02-22 12:47:13
Documents
17
Period of Report
2022-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea156005-8k_abvcbio.htm   iXBRL 8-K 28933
2 ADDENDUM TO COLLABORATION AGREEMENT ea156005ex10-3_abvcbio.htm EX-10.3 2061
3 AMENDMENT TO THE COLLABORATION AGREEMENT ea156005ex10-4_abvcbio.htm EX-10.4 7790
7 GRAPHIC image_001.jpg GRAPHIC 62662
8 GRAPHIC image_002.jpg GRAPHIC 50436
9 GRAPHIC image_003.jpg GRAPHIC 44330
  Complete submission text file 0001213900-22-008631.txt   426281

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20220222.xsd EX-101.SCH 3030
5 XBRL LABEL FILE abvc-20220222_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE abvc-20220222_pre.xml EX-101.PRE 22593
11 EXTRACTED XBRL INSTANCE DOCUMENT ea156005-8k_abvcbio_htm.xml XML 3174
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 22656906
SIC: 2834 Pharmaceutical Preparations